Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer SALT LAKE CITY, Jan. 04, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed an agreement with Bayer AG to in-license a new